Effect of Perioperative AntiHER-2 therapy on Early Breast Cancer Study - Biological phase.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Lapatinib (Primary) ; Hormones; Trastuzumab
- Indications Early breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms EPHOS-B
- 07 Jun 2017 Biomarkers information updated
- 12 Dec 2015 Interim results presented at the 38th Annual San Antonio Breast Cancer Symposium
- 17 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.